Background/Aims: Adult T-cell leukemia/lymphoma (ATL) is a very aggressive T cell malignancy that carries a poor prognosis, primarily due to its resistance to chemotherapy and to lifethreatening infectious complications. Interferon-alpha (IFNα) has been used in combination with the anti-retroviral drug zidovudine to treat patients with ATL. However, the efficacy of long-term therapy is significantly limited due to the systemic toxicity of IFNα. Methods: We utilized phage display library screening to identify short peptides that specifically bind to Jurkat T lymphocyte leukemia cells. By fusing the Jurkat-binding peptide to the C-terminus of IFNα, we constructed an engineered chimeric IFNα molecule (IFNP) for the treatment of ATL. Results: We found that IFNP exhibited significantly higher activity than wild type IFNα in inhibiting the growth of leukemia cells and inducing cell blockage at the G0/G1 phase. The synthetic IFNP molecule exerted its antitumor activity by upregulating the downstream genes involved in the STAT1 pathway and in apoptosis. Using a cell receptor binding assay, we showed that this Jurkat-binding peptide facilitated the binding affinity of IFNα to the cell surface type I IFN receptor. Conclusion: The isolated Jurkat-binding peptide significantly potentiates the therapeutic activity of IFNα in T lymphocyte leukemia cells. The engineered IFNP molecule may prove to a novel antitumor approach in the treatment of patients with ATL.
Introduction
Adult T-cell leukemia/lymphoma (ATL) is a very aggressive malignancy that is etiologically associated with infection by human T-cell lymphotropic virus type-I (HTLV-I) [1, 2] . Therapeutic interventions, including intensive chemotherapy, are often unsuccessful [3] . Patients have a poor prognosis primarily due to the resistance of leukemic cells to high doses of chemotherapy, large tumor burden, and life threatening infectious complications [4] [5] [6] .
Combined therapy with interferon-alpha (IFNα) and the anti-retroviral drug zidovudine (AZT) has been shown to induce responses in patients with ATL [7] [8] [9] . Interferons have significant antiviral and anti-proliferative properties. However, the impact of this combined antiviral treatment strategy on long-term survival of ATL patients remains unclear. The potency of long-term IFNα therapy is significantly limited due to its systemic toxicity [10, 11] . Therefore, it is imperative to develop novel therapeutic approaches to treat ATL.
We have previously engineered synthetic interferons by linking the native interferon to a short poly-charged peptide identified by cDNA fragment library screening [12, 13] . The addition of this poly-charged peptide enhances the binding of interferons to tumor cells, leading to superior tumor-killing activity. In this study, we used phage library screening to identify short peptides that specifically bind to Jurkat T lymphocyte leukemia cells. We reasoned that the Jurkat-binding peptides (JBP), when linked to the C-terminus of IFNα, would be able to potentiate the anti-tumor activity of IFNα in patients with ATL. In this study, we used Jurkat T lymphocyte leukemia cell as a disease model to examine whether the synthetic IFNα molecule can be used as an alternative approach for the treatment of ATL.
Materials and Methods

Cell culture
Three human cancer cell lines (T lymphocyte leukemia cell line Jurkat, breast cancer MCF7, and prostate cancer PC-3) were purchased from the American Type Culture Collection (ATCC, VA) and routinely cultivated in RPMI-1640 medium (Invitrogen, CA) with 10% fetal bovine serum (Invitrogen, CA), 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO 2 . The 293T cell line used for lentiviral packaging was purchased from ATCC (Manassas, VA) and cultured in DMEM supplemented with 10% FBS and 100 U/ml Penicillin-Streptomycin (Invitrogen, CA).
Phage display library screening of Jurkat binding peptides
Phage display library (Ph.D.-12 library, #E8110S, New England BioLabs, MA) was used to screen peptides that specifically bind to Jurkat T lymphocyte leukemia cells [14, 15] . Briefly, 2 × 10 9 phages in 1 ml RPMI-1640 medium were incubated with 1× 10 6 Jurkat cells for 1 hr at room temperature. The phage-cell complexes were further incubated at 37°C for 30 min to allow phagocytosis to occur. After binding, cells were washed 5 times with 5 ml TBST [TBS (10 mmol/l Tris pH 7.5, 150 mmol/l NaCl) containing 0.1% Tween 20] to remove the unbound and non-phagocytosed phages. Cells were collected by centrifuge at 3200 g for 5 min. The surface-bound phages were eluted for 20 min at room temperature with 1 ml elution buffer [0.2 M Glycine-HCl (pH 2.2), 1mg/ml BSA] and then neutralized with 150 μl 1 M Tris-HCl, pH 9.0. The Jurkat cell-internalized phages were released by lysing the cells in lysis buffer (1 mM triethylamine with 0.5% Triton X-100) for 1 min at RT and then immediately neutralizing the solution to pH 7.4 with 10 × PBS premixed with diluted HCl [16] . Both surface-bound and phagocytosed phages were infected into E. coli ER2738 and then purified using PEG 8000/NaCl solution.
After 4 rounds of surface panning, the DNA sequence of Jurkat-binding peptides (JBP) was amplified by PCR (Fig. 1A) . Primers used for PCR amplification were as follows: 5'-CTTTAGTGGTACCTTTCTATTCTCGAGTCT-3' (forward primer with XhoI) and 5'-CTTTCAACAGTTTCGTCTAGAACCTCCACC-3' (reverse primer with XbaI). The phage peptides were cloned into pJet vector using CloneJET PCR Cloning Kit (Thermo Fisher Scientific, CA) and sequenced for constructing engineered IFNα molecules.
Phage-ELISA assay
An ELISA assay was used to compare the binding affinity of the isolated Jurkat-binding peptides. About 2×10 4 Jurkat cells in 96 well V-bottom plate were incubated with block buffer (5% BSA/PBS, Sigma) for 1 hr at 37 °C. For comparison, MCF7 breast cancer and PC-3 prostate cancer cells were used as controls. Cells were pelleted by centrifuge at 3200g and resuspended in 100µl PBS buffer containing 1 × 10 10 phage particle. After incubation at RT for 1 hr, cells were pelleted by centrifuge at 3200g and washed with PBST for 5 × 5 min. For quantitation, cells were incubated with 100 µl PBS buffer containing HRP conjugated anti-M13 monoclonal antibody (1:5000, GE, NJ, USA) at 37 °C for 45 min. Cells were centrifuged at 3200g and washed with PBST for 5 × 5 min. Then 100 µl of TMB solution (BD, CA, USA) was added to each well and the plate was kept in the dark for ~15 min until a blue color developed. The reaction was stopped by adding 50 µl 1 N sulfuric acid. Final optical density was read at 450-650 nm on a microplate reader (Bio-Rad, CA, USA).
Recombinant plasmids and lentivirus production
After library screening and sequencing, one of the Jurkat cell-binding peptides (JBP) was selected. We ligated this peptide to the C-terminus of INFα to construct an engineered INFα fusion protein. The expression plasmid for the wild type IFNα was prepared as previously described [12, 13] . The synthetic interferon construct was generated by ligating the JBP sequence into the IFNα vector at the XhoI/XbaI restriction sites, and was designated as IFNP. The empty lentivirus vector and the vector containing the isolated JBP were used as control groups for the study. All constructs were confirmed by DNA sequencing. The putative structure of the IFNP was predicted using the online I-TASSER server (http://zhanglab.ccmb. med.umich.edu).
We used lentivirus vectors containing a green fluorescent protein (copGFP) gene to track lentiviral infection. Lentiviruses were packaged by the co-transfection of the constructed plasmids and pSPAX2/ pMD2G packing vectors using lipofectamine 2000 (Invitrogen, CA). The viral supernatants were collected at 48 h and 72 h post-transfection and used for cell transfection as previously described [17, 18] .
Infection of recombinant lentivirus
Jurkat cells were plated at a density of 5 × 10 5 / ml in six-well plate 24 hrs pre-transfection. Cells were infected with lentiviruses containing IFNP, INFα, JBP, and empty vector in the presence of 4 μg/ml polybrene (Sigma, MO). After incubation at 37°C for 24 hrs, the medium was replaced with a fresh medium in the absence of polybrene. Three days following viral infection, cells were selected by puromycin and copGFPpositive stable cells were used for this study.
Cell viability determination by the CCK8 assay Equal amount of stable Jurkat cells (5 × 10
3 ) were plated in 96-well plates and cultured for 48 hrs. For the cell viability assay, 10 µl CCK-8 solution (Thermo, Beijing, China) was added to each well and the plate was incubated at 37°C for 2 hrs. The absorbance at 450 nm was measured using microplate reader (Bio-rad, PA) [19] .
To examine the contribution of IFBP in co-treatment with Zidovudine, equal amount of stable Jurkat cells (1 × 10 4 ) were plated in 96-well plates and were treated with a low dose of zidovudine (AZT, 5 µM) for 48 hours. Cell viability was determined by the CCK8 assay.
Cell cycle analysis
After puromycin selection, stable Jurkat cells were collected and washed twice by 1 ml cold PBS. Cells were pelleted and resuspended in 1 ml fixation solution (300 µl PBS and 700 µl ethanol). After incubation at 4°C for 4 hrs, cells were centrifuged at 1000 rpm for 5 min and fixation solution was removed. After two washes with 1 ml PBS, the cells were pelleted and suspended in 0.5 ml propidium iodide staining solution (50 µg/ml PI, 20 µg/ml RNase A and 0.2% Triton X-100) and incubated in the dark at 37°C for 30 min. Cell suspensions were filtered through a 400-mesh sieve and were analyzed using a BD FACSCalibur flow cytometer (Becton Dickinson, Sparks, MD) [20] .
Gene expression by RT-PCR
Total RNA was extracted from Jurkat cells using the Trizol reagent (Invitrogen, CA). After removing the residual genomic DNA with DNase I (Invitrogen, CA), M-MLV Reverse Transcriptase (Invitrogen, CA) was used to synthesize cDNA [17, 21] 
Protein extraction and Western blot analysis
Cell total protein was extracted with RIPA buffer (Beyotime Biotechnology, Shanghai, China) supplemented with cocktail protease inhibitor (Roche), and the protein concentration was determined by a BCA protein assay kit (Beyotime Biotechnology, Shanghai, China). Twenty microgram total protein were separated by 5%-12% SDS polyacrylamide gel electrophoresis (SDS-PAGE) and were electrophoretically transferred to PVDF membranes (0.45 µm, Millipore, Billerica, MA, USA). After blocking with 5% skim milk in TBST [TBS (10 mmol/l Tris pH 7.5, 150 mmol/l NaCl) containing 0.1% Tween 20] at 37°C for 1 h, the membranes were incubated with monoclonal antibodies against p21 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), caspase 3 (Cell Signaling Technology, Beijing, China), STAT1 (Abcam, Shanghai, China), and β-ACTIN (Santa Cruz Biotechnology) at 4°C overnight. After washing for 3 × 5 min with TBST, the membranes were incubated with HRP-conjugated goat anti-mouse or goat anti-rabbit second antibodies (ZSGB-BIO, Beijing, China) at 37°C for 1 h. The immunocomplexes were detected with the enhanced chemiluminescence system (ECL, Thermo, Beijing, China) and X-ray film (Kodak, Beijing, China). Protein expression levels were determined semi-quantitatively by densitometric analysis with the Quantity One software (Bio-Rad, CA) [20, 22] .
For the detection of the secreted IFNα and IFNP proteins in cell supernatants, the supernatants were collected from stable Jurkat cells and 20 μl was separated on Mini-PROTEIN TGX gradient gel for Western detection using anti-IFNα antibody (Abcam, Shanghai, China).
Cell binding assay of IFNP
The binding of the engineered interferon to the Jurkat cell membrane receptor was compared using FACS. Jurkat cells were collected and stained with Trypan blue to make sure that there were > 90% viable cells. Cells (1 × 10 6 cells/tube in PBS) were incubated with equal amounts of the secreted IFNP and IFNα for 1 h at 37 °C. After washing with PBS, the cells were incubated with FITC-conjugated IFNα antibody (PBL, NJ), according to the manufacture's instruction. The FITC-conjugated mouse IgG (Abcam, MA) was used as the isotype control. Cells were analyzed using LSRFortessa (BD Biosciences, CA) and FlowJo software (FlowJo, OR, USA) to calculate the fluorescence intensity [12, 13] .
Statistical analysis.
All experiments were performed in triplicate and the data were expressed as mean ± SD. The significance was determined by Student's t test using SPSS 20.0 (IBM). P<0.05 was considered statistically significant.
Results
Construction of the IFNα-JBP hybrid molecule
To enhance the antitumor activity of IFNα in the ATL therapy, we first used a phage library display system to identify short peptides that specifically bind to Jurkat leukemia cells (Fig. 1A) . We hypothesized that the addition of a short, high-affinity peptide to the C-terminus of IFNα would be able to facilitate the binding of IFNα to Jurkat cell membranes, where the cytokine exerts its cell killing activity. We were particularly interested in short peptides that could induce phagocytosis in Jurkat cells.
To screen for high affinity peptides, Jurkat cells were incubated briefly with the phage library. Unphagocytosed surface-bound phages were stripped off by stripping buffer. The phagocytosed phages were recovered for the second round of phage display screening. After five rounds of screening, we identified phages that were specifically enriched in Jurkat cells. Through cloning and sequencing, we selected one phage that encodes an "eat-me" peptide for further study (Fig. 1B) . Using ELISA, we showed that this eat-me peptide was able to bind preferentially to Jurkat T lymphocyte leukemia cells as compared with MCF7 breast cancer and PC3 prostate cancer cells (Fig. 1C) . A public website blast search did not reveal any homologs in the protein databases.
To examine the role of this short peptide, we synthesized an IFNα hybrid molecule (IFNP) by linking the peptide to the C-terminus of IFNα (Fig. 1D ) and comparing the antitumor activity of IFNP with the wild type IFNα construct. Figure 1E shows the predicted protein structure of the synthesized IFNP molecule.
IFNP inhibits growth of Jurkat leukemia cells
We then compared the role of the synthetic IFNP with the wild type IFNα in inhibition of cell proliferation. Jurkat cells were transfected with lentiviruses carrying IFNP, IFNα, JBP control, and the vector, respectively, and were compared for their proliferative activity. Both IFNP and IFNα inhibited cell growth, but IFNP was superior to IFNα ( Fig. 2A) . By assessing cell viability, we found that IFNP induced a greater inhibition of cell growth than did IFNα (Fig. 2B, p<0.01) . Similarly, when co-treated with a low dose of Zidovudine (5 µM), IFBP exhibited the best therapeutic effect among treatment groups (Fig. 2D) .
IFNP induces the G0/G1 blockage
It has been shown that IFN-α induced cell cycle arrest and cell apoptosis in HTLV-1-infected T-cells that were collected from patients with ATL [23] . Given the fact that IFNP inhibits the growth of Jurkat cells, we used FACS to examine whether IFNP functions by affecting cell cycle. Stable Jurkat cells were collected and subjected to cell cycle analysis. The vector control and the JBP peptide control did not significantly affect the cell cycle. However, both IFNP and IFNα blocked Jurkat cells at the G1 stage, leading to the reduction of the number of tumor cells in S phase (Fig. 3) . However, IFNP showed a significantly better effect than IFNα in reducing the S phase population of Jurkat cells. 
Activation of the STAT1 pathway by IFNP
To delineate the mechanism underlying this enhanced activity by IFNP, we used RT-PCR to examine the expression of interferon pathway genes in the treated cells. We observed that 
both IFNP and IFNα upregulated several genes in the interferon pathway, including OAS2, MX1, ADPR, and IFIT1 (Fig. 4A) . Semi-quantitation of PCR band density showed that IFNP had a better effect than IFNα in activating the interferon pathway (Fig. 4B) . Similar data were also obtained in Jurkat cells using quantitative PCR (Fig. 4C) . The activation of the STAT1 pathway was also confirmed using Western blot (Fig. 4D) .
Upregulation of the apoptosis pathway by IFNP
We also examined the genes that related to apoptosis in the IFNP-treated cells. Using PCR, we showed that IFNP significantly upregulated Caspase 3 and p21 in Jurkat cells (Fig.  5A , 5B)(p < 0.01). The activation of the apoptosis pathway was also confirmed in the IFNPtransfected Jurkat cells using Western blotting (Fig. 5C, 5D ).
The enhanced binding of IFNP to the membrane of Jurkat cells
IFNα exerts its function through the binding and interaction with the specific cell surface type I IFN receptor. We assessed whether the binding of the synthetic IFNα to Jurkat cells was increased by addition of the phage peptide JBP. Using FACS, we showed that IFNP bound significantly better than IFNα to Jurkat cells (Fig. 6 ). These data suggest that the phage peptide enhances the antitumor effect by increasing the affinity of the cytokine to the cell membrane. 
Discussion
The combination of IFNα and AZT has been used to treat patients with ATL, but longterm therapy is limited due to the relatively low potency and systemic toxicity of IFNα. In this communication, we have identified a short peptide (JBP) that specifically binds to Jurkat T lymphocyte leukemia cells. By fusing this Jurkat-binding peptide to the C-terminus of IFNα, we demonstrate that the engineered IFNP molecule has significantly better antitumor activity than the wild type IFNα. IFNP induces cell blockage at the G0/G1 phase by upregulating the STAT1 and apoptosis pathways. Thus, this engineered IFNα-JBP molecule may serve as a novel antitumor agent in the treatment of patients with ATL.
The specific molecular mechanism underlying the enhanced antitumor effects of IFNP is still unknown. Using a cDNA in-frame library screening approach, we recently identified a short peptide derived from placental growth factor-2 (PLGF-2). Fusion of this short peptide to the C-terminus of IFNα and IFNγ induced significantly greater activity than did the wildtype counterparts in the inhibition of tumor cell growth, cell invasion and tumor colony formation [12, 13] . It is noteworthy that the PLGF-2 peptide is rich in positively charged amino acids, with 11 arginine (K) and lysine (L) residues at its N-terminus. The potentiation of interferon antitumor activity by this short PLGF-2 PCP peptide is related to its positively charged amino acids [12, 13] . However, the Jurkat-binding peptide isolated in this study is not positively charged and it contains only a single arginine (K) (Fig. 1B) . The Jurkat-binding peptide may function using a distinct mechanism to enhance the activity of the interferon.
The activity of cytokines is orchestrated by their binding to the extracellular matrix (ECM) of the target cell [24] . For example, the extracellular matrix-bound IFNα is more active than its soluble counterpart molecules [25] . The PLGF-2 aa123-144 peptide enhances the function of several growth factors through its extraordinarily strong interaction with extracellular matrix components [26] . Using a cell binding assay, we demonstrate in this study that the Jurkat-binding peptide promotes the binding of the interferon to the cell membrane receptor (Fig. 6) .
It should be noted that this is a proof-of-concept study launched to examine the role of the synthetic IFNP in vitro. A lentivirus vector system was used to deliver IFNP to Jurkat T lymphocyte leukemia cells. It will be important to determine whether the purified IFNP recombinant proteins are able to potentiate the antitumor activity. Thus, future studies are needed to validate the antitumor activity of IFNP, particularly when delivered in the form of purified recombinant proteins. Equally important is to demonstrate its antitumor activity in an animal xenograft tumor model using a commercial IFNα cytokine as the control.
The STAT pathway plays a critical role in the anti-infection of interferons [27] [28] [29] [30] . IFNα exerts its anti-tumor/anti-viral responses by inducing both apoptotic and non-apoptotic cell death through the activation of intrinsic and extrinsic pathways [31] [32] [33] . IFNα binds to its surface receptor and initiates a cascade of events that induces the phosphorylation of JAK1 and TYK2 kinases, followed by the activation of the signal transducer and activation of transcription (STAT) family transcription factors [34, 35] . After activation, the STAT complex is subsequently translocated to the nucleus, where it induces transcription of genes related to cell-cycle arrest and apoptosis [36, 37] . In this study, we demonstrate that the Jurkat-binding peptide promotes the binding of IFNα to the membrane receptor (Fig. 6) and upregulates the downstream genes that are associated with the STAT1 and apoptosis pathways (Figs.4, 5) . Thus, our data suggest that this short peptide may coordinate with IFNα, spatially regulating the signaling of the interferon in the cytokine cascade pathway. It would also be interesting to examine if the alteration of the signal pathway, using reagents as previously reported [38] [39] [40] [41] , will affect the therapeutic antitumor activity of the synthetic IFNP.
In summary, using phage library screening, we have identified a short peptide that specifically binds to Jurkat T lymphocyte leukemia cells. Fusion of this short peptide to the C-terminus of IFNα significantly potentiates the antitumor activity. By promoting the binding of IFNα to the cell membrane receptor and spatially regulating the signaling of the interferon, the JBP peptide blocks Jurkat leukemia cells at the G0/G1 phase through the activation of the STAT1 and apoptosis pathways. 
